<DOC>
	<DOCNO>NCT00779896</DOCNO>
	<brief_summary>This open label , prospective study evaluate therapeutic potential Tazarotene 0.1 % cream treatment Stage I-IIA CTCL . Patients Stage I-IIA disease enrol study . Tazarotene use 24 week patient follow 12 month .</brief_summary>
	<brief_title>Tazarotene 0.1 % Cream For Treatment Cutaneous T-Cell Lymphoma : A Prospective Study</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<mesh_term>Tazarotene</mesh_term>
	<criteria>Patients Stage IIIA CTCL must least 18 year age skin biopsy prior enrolment confirm diagnosis mycosis fungoides . Patients Stage &gt; IIA CTCL time enrolment Women pregnant plan get pregnant , unable/unwilling use adequate contraception Patients treat topical retinoid therapy past 3 month Patients receive systemic CTCL therapy systemic corticosteroid therapy within 30 day study start date Patients treat systemic isotretinoin bexarotene within 3 month prior study start date , systemic acitretin within 2 year prior study start date</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>To evaluate therapeutic potential tazarotene 0.1 % cream treatment Stage I-IIA CTCL . Patients Stage I-IIA disease enrol study</keyword>
	<keyword>Stage I-IIA disease CTCL</keyword>
</DOC>